Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Total Valuation
Harmony Biosciences Holdings has a market cap or net worth of $2.14B. The enterprise value is $1.49B.
Market Cap$2.14B
Enterprise Value$1.49B
Share Statistics
Harmony Biosciences Holdings has 57,532,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,532,600
Owned by Insiders22.05%
Owned by Institutions24.06%
Financial Efficiency
Harmony Biosciences Holdings’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 17.22%.
Return on Equity (ROE)0.22
Return on Assets (ROA)0.15
Return on Invested Capital (ROIC)17.22%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee2.67M
Profits Per Employee542.88K
Employee Count268
Asset Turnover0.72
Inventory Turnover21.79
Valuation Ratios
The current PE Ratio of Harmony Biosciences Holdings is 12.0. Harmony Biosciences Holdings’s PEG ratio is ―.
PE Ratio12.0
PS Ratio―
PB Ratio―
Price to Fair Value2.97
Price to FCF―
Price to Operating Cash Flow8.12
PEG Ratio―
Income Statement
In the last 12 months, Harmony Biosciences Holdings had revenue of 714.73M and earned 145.49M in profits. Earnings per share was 2.56.
Revenue714.73M
Gross Profit557.92M
Operating Income190.83M
Pretax Income191.80M
Net Income145.49M
EBITDA233.41M
Earnings Per Share (EPS)2.56
Cash Flow
In the last 12 months, operating cash flow was 259.38M and capital expenditures -648.00K, giving a free cash flow of 258.73M billion.
Operating Cash Flow259.38M
Free Cash Flow258.73M
Free Cash Flow per Share4.50
Dividends & Yields
Harmony Biosciences Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change6.43%
50-Day Moving Average34.78
200-Day Moving Average34.27
Relative Strength Index (RSI)64.51
Average Volume (3m)565.35K
Important Dates
Harmony Biosciences Holdings upcoming earnings date is Nov 4, 2025, Before Open (Confirmed).
Last Earnings DateJul 31, 2025
Next Earnings DateNov 4, 2025
Ex-Dividend Date―
Financial Position
Harmony Biosciences Holdings as a current ratio of 3.31, with Debt / Equity ratio of 22.26%
Current Ratio3.31
Quick Ratio3.27
Debt to Market Cap0.09
Net Debt to EBITDA-1.17
Interest Coverage Ratio10.91
Taxes
In the past 12 months, Harmony Biosciences Holdings has paid 46.31M in taxes.
Income Tax46.31M
Effective Tax Rate0.24
Enterprise Valuation
Harmony Biosciences Holdings EV to EBITDA ratio is 7.21, with an EV/FCF ratio of 7.70.
EV to Sales2.36
EV to EBITDA7.21
EV to Free Cash Flow7.70
EV to Operating Cash Flow7.66
Balance Sheet
Harmony Biosciences Holdings has $565.27M in cash and marketable securities with $172.09M in debt, giving a net cash position of -$393.18M billion.
Cash & Marketable Securities$565.27M
Total Debt$172.09M
Net Cash-$393.18M
Net Cash Per Share-$6.83
Tangible Book Value Per Share$9.60
Margins
Gross margin is 78.34%, with operating margin of 26.70%, and net profit margin of 20.36%.
Gross Margin78.34%
Operating Margin26.70%
Pretax Margin26.84%
Net Profit Margin20.36%
EBITDA Margin32.66%
EBIT Margin29.28%
Analyst Forecast
The average price target for Harmony Biosciences Holdings is $52.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$52.29
Price Target Upside37.42% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast17.74%
EPS Growth Forecast59.96%